Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan, follicular lymphoma grade I-IIIa, second-line

Protocol-ID: 306 V1.0 (Mini), RITU250/90YIT, foll. Lymphoma °I-IIIa, second line

Indication(s)

  • NHL, B-Cell Type, Follicular Grade I-IIIa; ICD-10 C82.9
  • NHL, B-Cell Type, Indolent
ST
Radiotherapy: 90Yttrium Ibritumomab-Tiuxetan
On day 1 after rituximab, 185 MBq111indium for dosimetry. On day 8 after rituximab, 15 MBq/kg 90 YIT to a maximum dose of 1200 MBq.
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician.

Valid since: 29.12.2014